Eusol Biotech Co.,Ltd.
Eusol Biotech Co.,Ltd. focuses on research and development of new drugs for the treatment of nerve injuries. The company's pipeline includes ES135, a recombinant human acidic fibroblast growth factor (rhFGF1) for spinal cord injury, and SM-1, a 3-in-1 combination sleeping aid. It also offers small molecule drugs including EPS221, a selective serotonin reuptake inhibitor; EPS222, a calcium channel… Read more
Eusol Biotech Co.,Ltd. (6652) - Total Assets
Latest total assets as of June 2025: NT$355.58 Million TWD
Based on the latest financial reports, Eusol Biotech Co.,Ltd. (6652) holds total assets worth NT$355.58 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Eusol Biotech Co.,Ltd. - Total Assets Trend (2019–2024)
This chart illustrates how Eusol Biotech Co.,Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Eusol Biotech Co.,Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Eusol Biotech Co.,Ltd.'s total assets of NT$355.58 Million consist of 99.1% current assets and 0.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 65.8% |
| Accounts Receivable | NT$8.51 Million | 2.3% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$77.00K | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Eusol Biotech Co.,Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eusol Biotech Co.,Ltd.'s current assets represent 99.1% of total assets in 2024, an increase from 0.0% in 2019.
- Cash Position: Cash and equivalents constituted 65.8% of total assets in 2024, up from 39.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 23.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 2.3% of total assets.
Eusol Biotech Co.,Ltd. Competitors by Total Assets
Key competitors of Eusol Biotech Co.,Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Eusol Biotech Co.,Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Eusol Biotech Co.,Ltd. generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Eusol Biotech Co.,Ltd. is currently not profitable relative to its asset base.
Eusol Biotech Co.,Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 43.56 | 38.14 | 2.88 |
| Quick Ratio | 43.56 | 38.14 | 2.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$344.88 Million | NT$ 381.31 Million | NT$ 33.19 Million |
Eusol Biotech Co.,Ltd. - Advanced Valuation Insights
This section examines the relationship between Eusol Biotech Co.,Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.50 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -7.9% |
| Total Assets | NT$377.91 Million |
| Market Capitalization | $12.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Eusol Biotech Co.,Ltd.'s assets below their book value (0.03 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Eusol Biotech Co.,Ltd.'s assets decreased by 7.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Eusol Biotech Co.,Ltd. (2019–2024)
The table below shows the annual total assets of Eusol Biotech Co.,Ltd. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$377.91 Million | -7.88% |
| 2023-12-31 | NT$410.26 Million | -6.93% |
| 2022-12-31 | NT$440.81 Million | -3.10% |
| 2021-12-31 | NT$454.91 Million | +61.83% |
| 2020-12-31 | NT$281.11 Million | -28.36% |
| 2019-12-31 | NT$392.40 Million | -- |